Shares of Novavax, Inc. (NASDAQ:NVAX) recorded -1.35% loss during trading session on January 11th, 2019. The script traded as low as $2.14 and last traded at $2.20. 7.96 million shares changed exchanged hands during trading, a drop of -1.74% from the 30-day average session volume of 7.82M shares. The firm had previously closed at $2.23. The company has $388.09M outstanding shares, price-to-earnings-growth ratio of 22.12 and a beta of 2.36. The company has a RSI of 55.66, ATR of 0.18 and a volatility of 6.38% this week. NVAX has a 52 week low price of $1.15 and a 52 week high price of $2.75.
Investors have identified the tech company Novavax, Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 853.80M, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Novavax, Inc. (NVAX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For NVAX, the company has in raw cash 74.08 million on their books with 0 currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 29.34 million total, with 126.68 million as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.
NVAX were able to record 140.41 million as free cash flow during the recently reported quarter of the year, this saw their quarterly net cash flow reduce by 60.4 million. In cash movements, the company had a total of 139.56 million as operating cash flow.
Potential earnings growth for Novavax, Inc. (NVAX)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Novavax, Inc. recorded a total of 7.74 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -0.08% coming in sequential stages and their sales for the third quarter reducing by -0.39%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 7.74 million trying to sell their products during the last quarter, with the result yielding a gross income of 49.64 million. This allows shareholders to hold on to 388.09M with the revenue now reading -120 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.13 cents a share).
Is the stock of NVAX attractive?
Having a look at the company’s valuation, the company is expected to record -0.46 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on NVAX sounds very interesting.
In related news, President, R&D Glenn Gregory M bought 13,007 shares of the company’s stock in a transaction that recorded on July 31st, 2019. The purchase was performed at an average price of 0.88, for a total value of 11,446. As the purchase deal closes, the President, R&D Glenn Gregory M now bought 20,000 shares of the company’s stock, valued at 32,800. Also, SVP, CBO and CFO Trizzino John bought 50,000 shares of the company’s stock in a deal that was recorded on May 14th, 2019. The shares were bought at an average cost of 1.64 per share, with a total market value of 138,965. Following this completion of disposal, the President and CEO now holds 100,000 shares of the company’s stock, valued at 164,620. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.16%.
1 out of 6 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Novavax, Inc. stock. 0 analysts has assigned a Sell rating on the NVAX stock. The 12-month mean consensus price target for the company’s shares has been set at $4.50.